HDAC9 and neoplasm: Histone deacetylase (HDAC) inhibitors represent a new emerging class of agents that induce a range of anticancer effects, including tumor cell apoptosis, cell cycle arrest, differentiation, senescence, modulation of immune responses, and altered angiogenesis [1].